Gan & Lee Pharmaceuticals. (603087.SS)

Gan & Lee Pharmaceuticals., a biopharmaceutical company, engages in the development, production, and commercialization of insulin analogs and medical devices in China. Its products include Basalin, an insulin glargine injection; Prandilin, an insulin lispro injection; Prandilin 25, an insulin lispro mix 75/25 injection; Rapilin, an insulin aspart injection; Rapilin 30, an insulin aspart 30 injection; and Similin 30, a mixed protamine human insulin injection. The company also offers GanleePen, an insulin injection device; and GanleeFine, an insulin pen needle. The company was formerly known as Beijing Gan & Lee Biotechnology Co., Ltd. and changed its name to Gan & Lee Pharmaceuticals. in April 2005. Gan & Lee Pharmaceuticals. was founded in 1998 and is headquartered in Beijing, the People's Republic of China.